{
    "organizations": [],
    "uuid": "842d12f51c2e42d4a59768020021f9271052a1d2",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-sublimity-therapeutics-completed-6/brief-sublimity-therapeutics-completed-64-mln-financing-to-further-development-of-new-oral-ulcerative-colitis-drug-candidate-idUSFWN1ST0BN",
    "ord_in_thread": 0,
    "title": "BRIEF-Sublimity Therapeutics - Completed $64 Mln Financing To Further Development Of New Oral Ulcerative Colitis Drug Candidate",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 22 (Reuters) -\n* SUBLIMITY THERAPEUTICS - COMPLETED $64 MILLION FINANCING TO FURTHER DEVELOPMENT OF STI-0529 FOR TREATMENT OF MODERATE TO SEVERE ULCERATIVE COLITIS\n* SUBLIMITY THERAPEUTICS SAYS FINANCING WAS CO-LED BY ORBIMED AND LONGITUDE CAPITAL WITH PARTICIPATION FROM HBM HEALTHCARE INVESTMENTS. Source text for Eikon:\n ",
    "published": "2018-05-22T18:24:00.000+03:00",
    "crawled": "2018-05-23T15:01:35.034+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "sublimity",
        "therapeutic",
        "completed",
        "million",
        "financing",
        "development",
        "treatment",
        "moderate",
        "severe",
        "ulcerative",
        "colitis",
        "sublimity",
        "therapeutic",
        "say",
        "financing",
        "orbimed",
        "longitude",
        "capital",
        "participation",
        "hbm",
        "healthcare",
        "investment",
        "source",
        "text",
        "eikon"
    ]
}